{"id":"NCT00324155","sponsor":"Bristol-Myers Squibb","briefTitle":"Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma","officialTitle":"A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-08","primaryCompletion":"2011-01","completion":"2013-10","firstPosted":"2006-05-10","resultsPosted":"2014-03-10","lastUpdate":"2014-11-03"},"enrollment":681,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Melanoma"],"interventions":[{"type":"DRUG","name":"Ipilimumab","otherNames":["MDX-010","BMS-734016"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Dacarbazine","otherNames":[]}],"arms":[{"label":"Arm A: Ipilimumab and Dacarbazine","type":"EXPERIMENTAL"},{"label":"Arm B: Placebo and Dacarbazine","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this clinical research study is to examine the safety and effectiveness (how well the drug works) of two different treatments for patients with melanoma. One treatment is an investigational compound (a drug that is not currently approved by the United States Food and Drug Administration \\[FDA\\]), know as Ipilimumab (also known as MDX-010 or BMS-734016) together with an approved chemotherapy drug called Dacarbazine","primaryOutcome":{"measure":"Overall Survival (OS)","timeFrame":"Date of randomization to 37 months through 5-year follow-up and up to approximately 76 months","effectByArm":[{"arm":"Ipilimumab and Dacarbazine","deltaMin":11.17,"sd":null},{"arm":"Placebo and Dacarbazine","deltaMin":9.07,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0009"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":11,"exclusionCount":null},"locations":{"siteCount":127,"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Chile","Czechia","France","Germany","Hungary","Ireland","Israel","Italy","Netherlands","Norway","Poland","Portugal","Russia","South Africa","Spain","Switzerland","Ukraine","United Kingdom"]},"refs":{"pmids":["25713437","25667295","21639810"],"seeAlso":["http://www.bms.com/studyconnect/Pages/home.aspx","http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx"]},"adverseEventsSummary":{"seriousAny":{"events":170,"n":247},"commonTop":["Nausea","Fatigue","Diarrhoea","Vomiting","Constipation"]}}